Oncoimmune, Inc.

University of Michigan

Oncolmmune, Inc.

Xincheng Zheng

Yang Liu

Pan Zheng

Wei Wu

Guo-Yun Chen

Steve Kunkel

Xi Chelsea Chen

Xi Cheng

Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

Methods of use of soluble CD24 for therapy of rheumatoid arthritis

Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.

Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis

Growing community of inventors

Ann Arbor, MI, United States of America

Xincheng Zheng